NXT007 enhances <i>in vitro</i> coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation.

ABSTRACT:

Background

NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In the future, emicizumab users may switch to NXT007.

Objectives

To investigate the effects of NXT007 in the coexistence of emicizumab on coagulation potential in vitro.

Methods

Coagulation potentials of HA plasma were determined by thrombin generation (TG) assays. NXT007 binding was analyzed by biolayer interferometry (BLI) and immunoblotting. Plasma levels of FIX-BsAb-FX ternary complexes were simulated using dissociation constant values for calculating theoretical coagulation potentials.

Results

In coexis

SUBMITTER: Yamaguchi K 

PROVIDER: S-EPMC12664447 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature